Nathanael G. Bailey, MD
Associate Professor of Pathology

Dr. Nathanael G. Bailey is a member of the Division of Hematopathology.

Office Location:
Hill Building 3rd Floor, Rm #353
3477 Euler Way
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-8780
Fax: 412-647-6332


  • BS - University of Kentucky, 2000
  • MD - West Virginia University, 2005
  • Residency - West Virginia University, 2005-9
  • Fellowship - Hematopathology, West Virginia University, 2009-10
  • Fellowship - Molecular Genetic Pathology, University of Michigan, 2010-1

Clinical Expertise

Dr. Bailey is active on the hematopathology service interpreting lymph node and bone marrow biopsies, reviewing blood films and body fluid specimens, interpreting flow cytometric studies, and providing consultative services on outside lymph node and bone marrow biopsy specimens. He additionally has experience interpreting genetic/genomic assays, and he is involved in bringing on new genetic tests for hematolymphoid neoplasms at the University of Pittsburgh.

Research Interests

Dr. Bailey's research interests include the molecular pathogenesis of hematolymphoid neoplasms and the translation of these findings into routine patient care. He participated in studies that examined the genomic landscape of splenic marginal zone lymphoma, T-cell prolymphocytic leukemia, and SÚzary syndrome. Dr. Bailey has led translational studies regarding the efficacy of immunohistochemical detection of mutant BRAF protein in hairy cell leukemia, and is involved in projects evaluating subclassification of peripheral T-cell lymphoma according to its "cell of origin". In addition, Dr. Bailey has written several book chapters and review articles.


Specialty Certification
07/2009-12/2019 American Board of Pathology - Anatomic and Clinical Pathology #09-076
09/2010-12/2020 American Board of Pathology - Hematopathology #S-10-278
09/2011-12/2021 American Board of Pathology and American Board of Medical Genetics - Molecular Genetic Pathology #S-11-090

Medical Licensure
09/2006-06/2014 State of WV, Medical License
03/2010-01/2017 State of MI, Controlled Substance
03/2010-01/2017 State of MI, Medical License
04/2016-12/2016 State of PA, Medical License

Selected Publications

  1. Polk A, Lu Y, Wang T, Seymour E, Bailey NG, Singer JW, Boonstra PS, Lim MS, Malek S, Wilcox RA. Colony-stimulating Factor-1 Receptor is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2016 Jun 22. pii: clincanres.3099.2015. [Epub ahead of print] PMID: 27334834.
  2. Behdad A, Bailey NG. Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. Surg Pathol Clin. 2016 Mar;9(1):41-54. doi: 10.1016/j.path.2015.09.008. Review. PMID: 26940267.
  3. Bailey NG, Elenitoba-Johnson KS. Mature T-cell leukemias: Molecular and Clinical Aspects. Curr Hematol Malig Rep. 2015 Dec;10(4):421-8. doi: 10.1007/s11899-015-0288-8. PMID: 26433891.
  4. Kiel MJ, Sahasrabuddhe AA, Rolland DC, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Jeffrey Medeiros L, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KS. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in SÚzary syndrome. Nat Commun. 2015 Sep 29;6:8470. doi: 10.1038/ncomms9470. PMCID: PMC4598843.
  5. Wang ML, Bailey NG. Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy. Arch Pathol Lab Med. 2015 Oct;139(10):1215-23. doi: 10.5858/arpa.2015-0203-RA. Review. PMID: 26414465.
  6. Weyand AC, Yanik GA, Bailey NG, Wu YM, Mody RJ, Castle VP. Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome. Pediatr Blood Cancer.2016 Jan;63(1):164-7. doi: 10.1002/pbc.25702. Epub 2015 Aug 8. PMID: 26257279.
  7. Joseph JR, Wilkinson DA, Bailey NG, Lieberman AP, Tsien CI, Orringer DA. Aggressive Myeloid Sarcoma Causing Recurrent Spinal Cord Compression. World Neurosurg. 2015 Sep;84(3):866.e7-10. doi: 10.1016/j.wneu.2015.04.017. Epub 2015 Apr 15. PMID: 25888811.
  8. Nie Z, Du MQ, McAllister-Lucas LM, Lucas PC, Bailey NG, Hogaboam CM, Lim MS, Elenitoba-Johnson KS. Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. Nat Commun. 2015 Jan 8;6:5908. doi: 10.1038/ncomms6908. PMID: 25569716.
  9. Brown NA, Betz BL, Weigelin HC, Elenitoba-Johnson KS, Lim MS, Bailey NG. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia. Am J Clin Pathol. 2015 Jan;143(1):89-99. doi: 10.1309/AJCPDN4Q1JTFGCFC. PMID: 25511147.
  10. Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG, Betz BL, Brown NA, Hristov AC, Wilcox RA, Miranda RN, Medeiros LJ, Jeon YK, Inamdar KV, Lim MS, Elenitoba-Johnson KS. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood. 2014 Dec 11;124(25):3768-71. doi: 10.1182/blood-2014-07-588434. Epub 2014 Oct 27. PMID: 25349176.
  11. Behdad A, Bailey NG. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med. 2014 Oct;138(10):1295-301. doi: 10.5858/arpa.2014-0291-CC. Review. PMID: 25268192.
  12. Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, Zhao L, Herling M, Lim MS, Elenitoba-Johnson KS. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014 Aug 28;124(9):1460-72. doi: 10.1182/blood-2014-03-559542. Epub 2014 May 13. PMCID: PMC4148768.
  13. Brown NA, Weigelin HC, Bailey N, Laliberte J, Elenitoba-Johnson KS, Lim MS, Betz BL. Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays. Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):590-600. doi: 10.1097/PAI.0000000000000024. PMID: 24503706.
  14. Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, Ristow K, Habermann TM, Thomas D, Ziesmer SC, Wellik LE, Lanigan TM, Witzig TE, Pittelkow MR, Bailey NG, Hristov AC, Lim MS, Ansell SM, Wilcox RA. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014 May 8;123(19):3007-15. doi: 10.1182/blood-2013-12-544809. Epub 2014 Feb 4. PMCID: PMC4014843.
  15. Bailey NG, Elenitoba-Johnson KS. Molecular diagnostics of T-cell lymphoproliferative disorders. Cancer J. 2014 Jan-Feb;20(1):48-60. doi: 10.1097/PPO.0000000000000016. Review. PMID: 24445765.